Related by context. All words. (Click for frequent words.) 70 thromboembolic 69 NATRECOR ® 68 NATRECOR R 68 tolvaptan 68 ischemic cardiomyopathy 67 invasive candidiasis 67 stable angina 67 antiarrhythmic drug 67 COPD exacerbations 66 intracerebral hemorrhage 66 peritumoral brain edema 66 acute myocardial infarction AMI 66 OAB symptoms 66 atherothrombotic disease 66 invasive aspergillosis 66 PRADAXA 66 severe exacerbations 65 ATACAND 65 β blockers 65 COPD exacerbation 65 lupus nephritis 65 decompensated heart failure 65 antithrombotic therapy 65 hemodialysis patients 65 Diabetic Macular Edema 65 hepatorenal syndrome 65 upper gastrointestinal bleeding 64 EXJADE 64 DVT PE 64 TNF antagonist 64 acute decompensated heart 64 HeFH 64 thrombotic events 64 reinfarction 64 AA Amyloidosis 64 acute coronary syndromes ACS 64 VTE prophylaxis 64 Cimzia TM 64 bosentan 64 eculizumab therapy 64 relapsed MM 64 hepatic encephalopathy 64 rFVIIa 64 canakinumab 64 retinal vein occlusion 64 non metastatic osteosarcoma 64 Exacerbations 64 NYHA Class II 64 VAPRISOL 64 systolic hypertension 64 unstable angina UA 64 PREZISTA r 64 candidemia 64 CYPHER R Sirolimus eluting 64 riociguat 64 recurrent VTE 64 alemtuzumab treated 63 onset atrial fibrillation 63 failure ADHF 63 beta blocker therapy 63 HIV HCV coinfected 63 angiotensin converting enzyme inhibitors 63 cirrhotic patients 63 hypercalcemia 63 Doxil ® 63 oral anticoagulation 63 postoperative atrial fibrillation 63 TMP SMX 63 oral FTY# 63 terlipressin 63 acute coronary syndrome 63 ruboxistaurin 63 carotid artery stenting 63 XIENCE V PROMUS Stent 63 myocardial ischemia 63 COPAXONE R 63 PEGylated interferon beta 1a 63 thromboprophylaxis 63 INCB# [003] 63 DAPT 63 salmeterol HFA MDI 63 forodesine 63 thromboembolic events 63 certolizumab 63 Acute Decompensated Heart Failure 63 macrovascular events 63 symptomatic BPH 63 dosing frequency 63 ZYVOX 63 eculizumab 63 aldosterone antagonist 63 NeuroStar TMS Therapy 63 myopathy rhabdomyolysis 63 nesiritide 63 antihypertensive therapy 63 posaconazole 63 teriflunomide 63 fluvastatin 63 CIMZIA ™ 63 atherothrombotic events 63 UA NSTEMI 63 ARCOXIA 63 antiplatelet medication 63 hemorrhagic complications 63 TMS Therapy 63 acute coronary syndromes 63 leukemia AML 63 intermittent claudication 63 acute humoral rejection 63 Nesiritide 63 calcineurin inhibitors 63 variceal bleeding 63 adult chronic ITP 63 hypokalemia 62 coronary intervention 62 cardiovascular hospitalization 62 hyperkalemia 62 acute ischemic stroke 62 definite stent thrombosis 62 mycophenolate mofetil 62 asthma exacerbation 62 clevidipine 62 Venous thromboembolism 62 intravenous bisphosphonates 62 haematologic 62 HSCT 62 venous thromboembolic disease 62 Aprotinin 62 ARIXTRA 62 elotuzumab 62 mixed hyperlipidemia 62 eosinophilic asthma 62 diabetic gastroparesis 62 antithrombotics 62 perioperative mortality 62 severe sepsis 62 micafungin 62 CYPHER Stent 62 recurrent glioblastoma multiforme 62 postoperative AF 62 pouchitis 62 IOP lowering 62 Erythropoietic therapies may 62 tigecycline 62 renal toxicity 62 VTE 62 lomitapide 62 herpetic keratitis 62 topical calcineurin inhibitors 62 debilitating complication 62 paclitaxel eluting stents 62 intracerebral haemorrhage 62 relapsed refractory multiple myeloma 62 thrombolytic agents 62 preserved ejection fraction 62 subclinical hypothyroidism 62 atherogenic dyslipidemia 62 intravenous diuretics 62 AGHD 62 recurrent venous thromboembolism 62 gouty arthritis 62 romiplostim 62 CTAP# Capsules 62 patients undergoing CABG 62 evaluable subjects 62 Traficet EN 62 sunitinib malate 62 coronary revascularization 62 CTEPH 62 visilizumab 62 Acute Coronary Syndromes ACS 62 symptomatic VTE 62 either acutely decompensated 62 cardiac toxicity 62 concomitant medications 62 systemic corticosteroids 62 ACTEMRA TM 62 relapsed SCLC 62 tiotropium 62 periprocedural 62 antimuscarinic 62 myocardial infarctions 62 EFFEXOR XR 62 PAOD 62 mRCC 61 Perforomist ™ Inhalation Solution 61 post thrombotic syndrome 61 Hepatocellular Carcinoma HCC 61 venous thromboembolism 61 pomalidomide 61 adalimumab 61 aldosterone antagonists 61 fibromyalgia syndrome 61 atrial fibrillation AF 61 neutropenic patients 61 non valvular atrial 61 peginterferon alfa 2a 61 APTIVUS r 61 CYPHER ® Stent 61 metastatic RCC 61 rosuvastatin Crestor 61 left ventricular dysfunction 61 prostate cancer CaP 61 fluticasone salmeterol 61 myeloproliferative disorders 61 antiplatelet therapy 61 relapsed multiple myeloma 61 arterial thromboembolic events 61 ARCALYST 61 Vaprisol 61 mycophenolate mofetil MMF 61 Infusion Reactions Severe 61 coronary revascularization procedures 61 antimicrobial prophylaxis 61 intravascular hemolysis 61 Bronchiectasis 61 velafermin 61 salmeterol fluticasone 61 alvimopan 61 pericardial effusion 61 paroxysmal atrial fibrillation 61 DEFINITY ® 61 placebo controlled clinical 61 recurrent GBM 61 corticosteroid therapy 61 serum phosphate 61 thromboembolism 61 lactic acidosis 61 antithrombotic agents 61 XIENCE V demonstrated 61 refractory angina 61 chronic GVHD 61 PRTX 61 NYHA Class III 61 invasive fungal infections 61 refractory NSCLC 61 acute STEMI 61 nephrotoxicity 61 RE LY ® 61 pulmonary exacerbation 61 Hydroxyurea 61 diabetic neuropathic pain 61 calcineurin inhibitor 61 Platinol ® 61 GOUT 61 oral diclofenac 61 FASLODEX 61 INFERGEN 61 nosocomial pneumonia 61 diabetic nephropathy 61 pulmonary arterial hypertension PAH 61 NOMID 61 comorbid conditions 61 ximelagatran 61 tachyarrhythmias 61 null responder 61 AEGR 61 recurrent myocardial infarction 61 thromboembolic disease 61 revascularization procedures 61 INTEGRILIN R 61 vidofludimus 61 eritoran 61 warfarin therapy 61 ICD shocks 61 acute GvHD 61 serum phosphorous 61 thrombotic complications 61 Nocturia 61 intravesical therapy 61 tumor lysis syndrome 61 myeloproliferative neoplasms 61 chronic HCV infection 61 Nilotinib 61 alteplase 61 antiarrhythmic drugs 61 null responder HCV 61 chronic ITP patients 61 superficial bladder cancer 61 T1DM 61 heparin induced thrombocytopenia 61 divalproex sodium 61 Critical Limb Ischemia CLI 61 resistant hypertension 61 MACCE 61 ULORIC 61 Non inferiority 61 landmark ATHENA trial 61 unstable angina pectoris 61 MULTAQ 61 RSD# oral 61 ISTODAX 61 atypical Hemolytic Uremic Syndrome 61 esophageal candidiasis 61 AGILECT R 61 antiplatelet drugs 61 candesartan cilexetil 61 thromboembolic complications 61 Octreolin 61 Ranolazine 61 ICD implantation 61 imipenem 61 REMICADE ® 61 IFN beta 60 TAXUS Stent 60 Lung transplantation 60 ACCOMPLISH 60 DOXIL 60 hyperphenylalaninemia HPA due 60 CYPHER ® 60 dyslipidaemia 60 HBeAg positive patients 60 muraglitazar 60 pulmonary exacerbations 60 Major Depressive Disorder MDD 60 deep venous thromboses 60 acutely decompensated heart 60 macroalbuminuria 60 AST ALT 60 CMV disease 60 AFib 60 eplerenone 60 CIMZIA TM certolizumab pegol 60 glomerular filtration 60 symptomatic carotid stenosis 60 acute exacerbations 60 prophylactic therapy 60 Arcalyst 60 ularitide 60 decompensation 60 venous thrombosis 60 Val HeFT 60 cardiac biomarkers 60 elective PCI 60 PONV 60 Insulin PH# 60 ALT flares 60 oral rivaroxaban 60 Acute Myocardial Infarction 60 mg/m2 dose 60 carotid artery stenting CAS 60 Severe VOD 60 psoriatic arthritis PsA 60 acute PAO 60 ESRD patients 60 APPRAISE 60 hyperuricemia 60 Pemetrexed 60 KRAS mutations occur 60 cardiovascular hospitalizations 60 carotid endarterectomy CEA 60 CHARM Added 60 homozygous familial hypercholesterolemia 60 antithrombotic therapies 60 ACZ# 60 pheochromocytoma 60 infective endocarditis 60 Elitek 60 opioid induced bowel dysfunction 60 Keppra R 60 nonvertebral fractures 60 Hypotension 60 CRVO 60 dual antiplatelet therapy 60 MGd 60 antibody mediated rejection 60 chronic angina 60 Chronic Migraine 60 Adjuvant chemotherapy 60 MADIT II 60 patients undergoing percutaneous 60 noninfectious uveitis 60 GvHD 60 octreotide LAR 60 RE LY 60 Contrast Induced Nephropathy CIN 60 BARACLUDE ® 60 heterozygous FH 60 severe hypoglycemic 60 reperfusion injury 60 uncontrolled hypertension 60 PSVT 60 paroxysmal AF 60 ACC AHA 60 HoFH 60 mg administered orally 60 FOLFOX4 60 RAPTIVA 60 adrenal insufficiency 60 isolated systolic hypertension 60 pegylated interferon alfa 60 colorectal liver metastases 60 mucosal healing 60 clopidogrel Plavix 60 cerebrovascular events 60 FIRMAGON 60 sargramostim 60 lipid lowering therapy 60 oral allopurinol 60 CIMZIA TM 60 Tiotropium 60 OHR/AVR# 60 NP2 Enkephalin 60 chronic thromboembolic pulmonary 60 potassium sparing diuretics 60 relapsed AML 60 uncontrolled asthma 60 partial onset seizures 60 glycated hemoglobin levels 60 nitrofurantoin 60 systolic dysfunction 60 CALGB # [002] 60 renal impairment 60 abatacept 60 renal dysfunction 60 GnRH agonists 60 bronchial hyperresponsiveness 60 VADT 60 FluCAM arm 60 corticosteroid dose 60 hypercholesterolaemia 60 briakinumab 60 6R BH4 60 ponatinib 60 nonfatal MI 60 therapeutic regimens 60 SJIA 60 repeat revascularization 60 Unstable Angina 60 pseudobulbar affect PBA 60 intravitreal injections 60 Myelodysplastic syndromes MDS 60 relapsing remitting MS RRMS 60 vertebral fracture 60 hoFH patients 60 lipid lowering agents 60 oxycodone CR 60 gross hematuria 60 treprostinil 60 VIIBRYD 60 elevated triglyceride levels 60 cSSSI 60 atrial fibrillation AFib 60 elevated LDL cholesterol 60 myelosuppression 60 ipsilateral stroke 60 PNH patients 60 Coronary Artery Bypass Graft 60 elevated ALT 60 proliferative diabetic retinopathy 60 Moxifloxacin 60 tirofiban 60 LEVAQUIN 60 oral anticoagulant 60 cardiovascular mortality 60 thrombolytic therapy 60 Eltrombopag 60 galiximab 60 NSAID therapy 60 symptomatic paroxysmal AF 60 Ventavis 60 hyperbilirubinemia 60 cobiprostone 60 urate lowering 60 nicardipine 60 hypercholesterolemia 60 serum calcium levels 60 adalimumab Humira 60 azacitidine 60 invasive fungal infection 60 bacteremia 60 doxorubicin docetaxel 60 virological failure 60 Neovascular AMD 60 NYHA functional class 60 severe hypersensitivity reactions 60 LANTUS ® 60 platelet inhibitor 60 KAPIDEX 60 oral anticoagulant therapy 60 hyperphosphatemia 60 decitabine 60 cinacalcet 60 Ophena TM 60 deferiprone 60 glucocorticoid therapy 60 overactive bladder syndrome 60 solifenacin 60 neurogenic orthostatic hypotension 60 tocilizumab 60 severe gastroparesis 60 AVANDIA 60 platelet reactivity 59 silent ischemia 59 recurrent DVT 59 prolonged QT interval 59 EVIZON 59 direct thrombin inhibitors 59 erythropoietic 59 refractory gout 59 angiotensin receptor blocker ARB 59 drug eluting stent DES 59 ara C 59 ARCALYST ® 59 angina pectoris 59 haloperidol Haldol 59 refractory AML 59 atherothrombosis 59 systemic corticosteroid 59 Carotid Revascularization Endarterectomy vs. 59 SHPT 59 ventricular tachyarrhythmia 59 FROVA 59 cryptogenic stroke 59 endothelin receptor antagonists 59 aclidinium 59 antiplatelet therapies 59 plasminogen activators 59 rhinosinusitis 59 GP IIb IIIa inhibitors 59 vertebral compression fractures 59 cardiovascular morbidity 59 lipid lowering drugs 59 levosimendan 59 tegaserod 59 postoperative mortality 59 rilonacept 59 gout flares 59 Renal dysfunction 59 hypoglycemic episodes 59 asthma exacerbations 59 chronic HCV 59 T2DM 59 LHRH antagonists 59 complement inhibitor eculizumab 59 favorable pharmacokinetic profile 59 grade cervical intraepithelial 59 cardiac dysfunction 59 secondary hyperparathyroidism 59 allogeneic HSCT 59 VaD 59 microvascular complications 59 myelofibrosis 59 APTIVUS 59 Betaferon R 59 certolizumab pegol 59 thrombocytopenic 59 relapsing multiple sclerosis 59 Golimumab 59 Gemzar ® 59 BENICAR 59 Glypromate 59 MYCAMINE 59 Vimpat ® 59 vWD 59 colorectal adenoma 59 acute myocardial infarction MI 59 COPD 59 nab paclitaxel 59 biologic DMARD 59 biologic therapy 59 lipid disorders 59 febrile neutropenia 59 nonrandomized 59 venous thromboembolic events 59 lymphoproliferative disorder 59 vinorelbine 59 co morbidities 59 TYGACIL 59 pulmonary hypertension PH 59 TREDAPTIVE 59 metastatic neuroendocrine tumors 59 dose cohort 59 dual endothelin receptor antagonist 59 antithrombotic 59 antiplatelet agents 59 sJIA 59 Exacerbation 59 acute migraine 59 antiplatelet agent 59 leukemia ALL 59 occlusive disease 59 Congestive Heart Failure 59 C1 INH 59 ibandronate 59 acute myocardial infarctions 59 BROVANA 59 Natalizumab 59 ADAGIO study 59 anticoagulation therapy 59 hemodynamically stable 59 efalizumab 59 diastolic heart 59 oral corticosteroid 59 Uncontrolled hypertension 59 ribavirin therapy 59 brivaracetam 59 BENICAR HCT 59 EURIDIS 59 PRIMO CABG2 59 Prehypertension 59 oral Xeloda 59 ziconotide 59 relapsing remitting multiple sclerosis 59 Thrombolysis 59 proton pump inhibitor PPI 59 lipid parameters 59 Quinamed 59 gastrointestinal GI motility disorders 59 dexmedetomidine 59 nondiabetic patients 59 icatibant 59 atrioventricular block 59 AVONEX ® 59 antibiotic regimens 59 phase IIb study 59 Navelbine ® 59 relapsing MS 59 CRBSI 59 status asthmaticus 59 severe asthma exacerbations 59 endometrial hyperplasia 59 Major Depressive Disorder 59 tolterodine ER 59 flurpiridaz F 59 postoperative morbidity 59 lapatinib Tykerb 59 PREZISTA r arm 59 MEND CABG 59 dosing cohort 59 CYT# potent vascular disrupting 59 MACUGEN 59 COU AA 59 Urocortin 2 59 ertapenem 59 Xanafide 59 INC# 59 bronchodilation 59 NSTE ACS 59 acutely decompensated congestive heart 59 INVEGA ® 59 thetreatment 59 venous blood clots 59 hyperacute 59 esophageal varices 59 GFT# 59 untreated OSA 59 HCV SPRINT 59 Serious adverse reactions 59 androgen deprivation 59 acne vulgaris 59 sitaxsentan 59 postsurgical 59 #.#mg/dL 59 schizophrenia CIAS 59 malignant neoplasms 59 intracranial stenosis 59 bacterial prostatitis 59 ENDEAVOR II 59 complete remissions 59 severe aortic stenosis 59 nonadherence 59 REMINYL ® 59 prostate cancer CRPC 59 metastatic lung cancer 59 LEUKINE 59 binary restenosis 59 elevated uric acid 59 detrusor overactivity 59 rNAPc2 59 5-FU/LV 59 IBS C 59 Raptiva ® 59 perioperative morbidity 59 TEAEs 59 levetiracetam 59 immunosuppressives 59 TACI Ig 59 ancrod 59 anti arrhythmic drug 59 myelodysplastic syndrome MDS 59 perioperatively 59 progressive PsA 59 Stent thrombosis 59 chemotherapy induced neutropenia 59 dosage regimens 59 alfuzosin 59 Pegasys ® 59 Toxicities 59 Myocardial Infarction Study 59 acute leukemias 59 eosinophilic pneumonia 59 myocardial infarction MI 59 RRMS patients 59 postsurgical pain 59 ischemic stroke 59 Acute MI 59 microalbuminuria 59 gefitinib Iressa 59 oxypurinol 59 LHRH agonists 59 Zevalin consolidation 59 HbA 1c levels 59 pulmonary arterial hypertension 59 elevated intraocular pressure 59 severe neutropenia 59 tasocitinib 59 Severe Sepsis 59 prednisone prednisolone 59 HMG CoA reductase inhibitors 59 reflux disease GERD 59 H. pylori eradication 59 recurrent ischemia 59 metastatic GIST 59 Acute Coronary Syndrome 59 inhaled corticosteroid ICS 59 Navelbine 59 ischemic complications 59 MAGE A3 ASCI 59 post herpetic neuralgia 59 Lamictal XR 59 xanthine oxidase inhibitor 59 Phase #/#a 59 PROMACTA 59 antihypertensive agents 59 noncardiac surgery 59 induce orthostatic hypotension 59 overt nephropathy 59 FFR guided treatment 59 Aloxi injection 59 DDP# 59 AAT deficiency 59 lesinurad 59 basiliximab 59 leukotriene receptor antagonists 59 tipranavir r 59 constipation OIC 59 clinical pharmacology studies 59 tapentadol ER 59 CLL SLL 59 non squamous NSCLC 58 polypharmacy 58 antiemetics 58 Hepatotoxicity 58 atrial arrhythmias 58 Teriflunomide 58 dopaminergic therapy 58 curative resection 58 Valsartan 58 benign prostatic hypertrophy BPH 58 mixed dyslipidemia 58 revascularizations 58 phase IIa clinical 58 ZACTIMA 58 locoregional 58 idarubicin 58 naïve HCV 58 HBeAg negative patients 58 ventricular arrhythmia 58 HuMax EGFr 58 angiographic outcomes 58 chemoradiotherapy 58 Dose escalation 58 tolterodine 58 juvenile idiopathic arthritis 58 hematuria 58 bacteriuria 58 APTIVUS ritonavir 58 Dacogen injection 58 polyp recurrence 58 Percutaneous Coronary Intervention 58 pharmacokinetic interactions 58 Warfarin Coumadin 58 hyperglycaemia 58 interferon beta therapy 58 nonalcoholic steatohepatitis 58 recurrent glioblastoma 58 Thrombocytopenia 58 ticlopidine 58 cell lymphoma CTCL 58 postoperative ileus POI 58 smoldering multiple myeloma 58 NYHA class 58 Fibrillex TM 58 secondary efficacy endpoints 58 elevated troponin 58 Acute Ischemic Stroke 58 fluid overload 58 glatiramer acetate 58 ELACYT 58 parkinsonian symptoms 58 elevated serum creatinine 58 PEGINTRON TM 58 EchoCRT 58 metaglidasen 58 afib 58 INCB# [001] 58 morbidity mortality 58 neurologic complications 58 psychiatric comorbidities 58 ExTRACT TIMI 58 Mipomersen 58 gemifloxacin 58 ulcerative colitis UC 58 cSSSIs 58 Eisenmenger syndrome 58 Overactive Bladder 58 STEMI 58 Rheumatoid Arthritis RA 58 chronic rhinosinusitis 58 hour bronchodilation 58 chronic noncancer pain 58 pharmacokinetic PK 58 neovascular diseases 58 Increlex ® 58 SPIRIVA HandiHaler 58 cardiogenic shock 58 Microalbuminuria 58 renal insufficiency 58 TAXUS Express Stent 58 extrapyramidal symptoms 58 argatroban 58 Benign Prostatic Hyperplasia BPH 58 olmesartan 58 metastatic malignant 58 GAMMAGARD 58 dose escalation phase 58 subtrochanteric 58 hypoparathyroidism 58 nephrotoxic drugs 58 interferon ribavirin 58 amoxicillin clavulanate 58 AZILECT 58 Mucositis 58 PTNS 58 Torsades de Pointes 58 HCV infected 58 diabetic retinopathy DR 58 neovascular AMD 58 acid suppressive therapy 58 hepatitis C genotype 58 reteplase 58 myocardial perfusion imaging 58 treatment naive genotype 58 Xelox 58 symptomatic intracranial 58 Triapine R 58 metformin sulfonylurea 58 thrombolytic agent 58 CDAD 58 SSRI SNRI 58 ONTARGET 58 amphotericin B 58 Combination therapy 58 valvular disease 58 infliximab Remicade 58 aortic valve stenosis 58 levodopa carbidopa 58 pain palliation 58 exacerbations 58 acadesine 58 TORISEL 58 delayed CINV 58 PRT# 58 protease inhibitor PI 58 carotid stenting 58 PASI scores 58 bucindolol 58 primary hypercholesterolemia 58 sustained virologic response 58 Patient Outcomes 58 idiopathic pulmonary fibrosis IPF 58 antiepileptic drugs AEDs 58 ranolazine 58 acid suppressive medication 58 risperidone Risperdal 58 VTEs 58 Phase Ib clinical 58 overactive bladder OAB 58 convenient dosing regimen 58 rheumatoid arthritis osteoarthritis ankylosing 58 PGTC seizures 58 TAVR 58 CoFactor 58 myeloproliferative diseases 58 hepatotoxicity 58 ISIS # 58 antidiabetic therapy 58 quetiapine Seroquel 58 ipratropium bromide 58 Bezielle 58 immune thrombocytopenic purpura ITP 58 coinfected patients 58 SNRI 58 INTEGRILIN 58 vernakalant hydrochloride 58 pathologic fractures 58 S. aureus infection 58 phase IIb clinical 58 angiotensin converting enzyme inhibitor 58 AA amyloidosis 58 Oral mucositis 58 allopurinol 58 Scale EDSS score 58 transaminase elevations 58 HES CEL 58 Decitabine 58 opioid induced constipation 58 juvenile idiopathic arthritis JIA 58 ORENCIA ® 58 Ozarelix 58 ACIPHEX 58 cisplatin chemotherapy 58 discontinuations due 58 CANCIDAS 58 trial evaluating Prochymal 58 cerebral vasospasm 58 Events MACE 58 JAK inhibitor 58 lipid abnormalities 58 gatifloxacin 58 sUA 58 receiving VELCADE 58 pamidronate 58 STRIDE PD 58 AVAPRO 58 opioid dependent 58 YONDELIS 58 tolerability profiles 58 angiotensin receptor blockers 58 Adalimumab 58 adverse reactions ≥ 58 zonisamide SR 58 carcinoid tumors 58 SYMBICORT 58 liposomal amphotericin B 58 morphometric vertebral fractures 58 Postoperative complications 58 symptom exacerbation 58 anastomotic leak 58 severe hypoglycemia 58 lipid lowering therapies 58 cIAI 58 clinically meaningful reductions 58 CAPHOSOL 58 beta blocker 58 cilengitide 58 Welchol 58 asymptomatic carotid stenosis 58 biliary tract cancer 58 achieved ACR# 58 Vascugel 58 dopamine partial agonist 58 Febrile neutropenia 58 virologic failure 58 metastatic malignant melanoma 58 oral Hycamtin 58 denufosol 58 acromegalic patients 58 HCV infection 58 carotid stenosis 58 GERD symptoms 58 refractory CLL 58 fosamprenavir 58 hepatic failure 58 EDARBI 58 heavily pretreated 58 advanced hepatocellular carcinoma 58 pyridostigmine 58 carotid artery stenosis 58 hyperglycemia 58 progressive dyspnea 58 Salmeterol 58 tiotropium bromide 58 OSAHS 58 follicular lymphoma FL 58 Severe Primary IGFD 58 glufosfamide 58 unfractionated heparin UFH 58 EDSS scores 58 antiplatelet medications 58 bronchospasm 58 systemic fungal infections 58 aHUS 58 Azilect ® 58 anterior uveitis 58 unfavorable cytogenetics 58 bendamustine 58 Non Alcoholic Fatty 58 imatinib therapy 58 pharmacodynamic PD 58 immunomodulatory therapy 58 Myelodysplastic Syndrome MDS 58 CVD mortality 58 MCyR 58 oral ridaforolimus 58 bisphosphonate therapy 58 arterial thrombosis 58 duodenal ulcer